32974838 29359417 29048712 31030810 29765290 28670147 29928908 28350322 35136579 33769892 33939226 31833714 28326849 31435896 28470862 31353761 32597029 29899890 31778283 - Search Results

Year	Number of Results
2017	5
2018	5
2019	4
2020	5
2021	3
2023	0

1

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.

Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T. Solms A, et al. Ann Hematol. 2020 Nov;99(11):2689-2698. doi: 10.1007/s00277-020-04280-3. Epub 2020 Sep 24. Ann Hematol. 2020. PMID: 32974838 Free PMC article. Clinical Trial.

2

Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A.

Dunn AL, Ahuja SP, Mullins ES. Dunn AL, et al. Haemophilia. 2018 May;24(3):e84-e92. doi: 10.1111/hae.13403. Epub 2018 Jan 23. Haemophilia. 2018. PMID: 29359417

3

Efficacy and safety of Nuwiq^® (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.

Zozulya N, Kessler CM, Klukowska A, von Depka M, Hampton K, Hay CRM, Jansen M, Bichler J, Knaub S, Rangarajan S. Zozulya N, et al. Haemophilia. 2018 Jan;24(1):70-76. doi: 10.1111/hae.13351. Epub 2017 Oct 19. Haemophilia. 2018. PMID: 29048712

4

Hemophilia in a Changing Treatment Landscape.

Pelland-Marcotte MC, Carcao MD. Pelland-Marcotte MC, et al. Hematol Oncol Clin North Am. 2019 Jun;33(3):409-423. doi: 10.1016/j.hoc.2019.01.007. Epub 2019 Mar 29. Hematol Oncol Clin North Am. 2019. PMID: 31030810 Review.

5

Extended Half-Life Factor VIII and Factor IX Preparations.

Graf L. Graf L. Transfus Med Hemother. 2018 Apr;45(2):86-91. doi: 10.1159/000488060. Epub 2018 Mar 21. Transfus Med Hemother. 2018. PMID: 29765290 Free PMC article. Review.

6

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

Lieuw K. Lieuw K. J Blood Med. 2017 Jun 15;8:67-73. doi: 10.2147/JBM.S103796. eCollection 2017. J Blood Med. 2017. PMID: 28670147 Free PMC article. Review.

7

Advancement in the treatment of haemophilia.

Bhardwaj R, Rath G, Goyal AK. Bhardwaj R, et al. Int J Biol Macromol. 2018 Oct 15;118(Pt A):289-295. doi: 10.1016/j.ijbiomac.2018.06.084. Epub 2018 Jun 19. Int J Biol Macromol. 2018. PMID: 29928908 Review.

8

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Mancuso ME, Santagostino E. Mancuso ME, et al. J Clin Med. 2017 Mar 28;6(4):39. doi: 10.3390/jcm6040039. J Clin Med. 2017. PMID: 28350322 Free PMC article. Review.

9

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.

Witarto BS, Visuddho V, Witarto AP, Sutanto H, Wiratama BS, Wungu CDK. Witarto BS, et al. F1000Res. 2021 Oct 15;10:1049. doi: 10.12688/f1000research.73884.3. eCollection 2021. F1000Res. 2021. PMID: 35136579 Free PMC article.

10

Current and Future Options of Haemophilia A Treatments.

Miesbach W, Eladly F. Miesbach W, et al. Expert Opin Biol Ther. 2021 Nov;21(11):1395-1402. doi: 10.1080/14712598.2021.1908993. Epub 2021 Apr 1. Expert Opin Biol Ther. 2021. PMID: 33769892

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

19 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year